Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06864143 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,320
- Enrollment target
NCT06864143 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 1,320 participants.
The verdict
NCT06864143, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,320 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
Interventions
- BIOLOGICAL mRNA-1083 Composition 1 Dose A Lot A
- BIOLOGICAL mRNA-1083 Composition 1 Dose A Lot B
- BIOLOGICAL mRNA-1083 Composition 1 Dose B
- BIOLOGICAL mRNA-1083 Composition 1 Dose C
- BIOLOGICAL mRNA-1083 Composition 2 Dose A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,320 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2025-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06864143
The ClinicalTrials.gov registry entry for NCT06864143 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mRNA-1083 Composition 1 Dose A Lot A is the first listed.
NCT06864143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06864143 about?
NCT06864143 is a clinical study titled "A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age". The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
What is the current status of trial NCT06864143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,320 participants. The study started on 2025-03-07. Estimated completion is 2025-10-13.
What interventions are being tested in trial NCT06864143?
The interventions under investigation include: mRNA-1083 Composition 1 Dose A Lot A (BIOLOGICAL), mRNA-1083 Composition 1 Dose A Lot B (BIOLOGICAL), mRNA-1083 Composition 1 Dose B (BIOLOGICAL), mRNA-1083 Composition 1 Dose C (BIOLOGICAL), mRNA-1083 Composition 2 Dose A (BIOLOGICAL).
Who is sponsoring clinical trial NCT06864143?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.